The global mouth ulcer treatment market size was surpassed at USD 1.62 billion in 2023 and is expected to hit around USD 2.39 billion by 2033, growing at a CAGR of 3.95% from 2024 to 2033.
The mouth ulcer treatment market is witnessing significant growth globally due to the rising prevalence of oral health issues and an increasing awareness regarding oral hygiene. Mouth ulcers, also known as canker sores, are a common oral condition characterized by painful sores or lesions in the mouth lining. These ulcers can be caused by various factors such as stress, injury, vitamin deficiencies, or underlying health conditions. As a result, the demand for effective treatment options to alleviate pain and promote healing has surged, driving the growth of the mouth ulcer treatment market.
The growth of the mouth ulcer treatment market is propelled by the uptick in the prevalence of mouth ulcers globally, stemming from various lifestyle-related factors and dietary habits. Additionally, heightened awareness campaigns surrounding oral health have prompted individuals to seek treatment for oral conditions, including mouth ulcers, at an earlier stage. Technological advancements in treatment options, ranging from topical applications to advanced therapeutic procedures, have also contributed significantly to market expansion. Moreover, the increasing healthcare expenditure and accessibility to oral healthcare services further fuel market growth, as patients prioritize managing mouth ulcers effectively to alleviate discomfort and promote healing.
Report Coverage | Details |
Revenue Share of North America in 2023 | 37% |
CAGR of Asia Pacific from 2024 to 2033 | 5.05% |
Revenue Forecast by 2033 | USD 2.39 billion |
Growth Rate from 2024 to 2033 | CAGR of 3.95% |
Base Year | 2023 |
Forecast Period | 2024 to 2033 |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The analgesics and corticosteroids segment dominated the market in 2023 and is also expected to grow at the fastest CAGR over the forecast period from 2024 to 2033, owing to the high prescription rate of these products as painkillers in the global market. They are used as painkillers in the treatment of dental sores.
Corticosteroid has anti-inflammatory properties that help in lowering inflammation caused due to infection. In addition, it binds with intracellular receptors and alters gene expression, thereby inhibiting the action of microbes. Analgesics and corticosteroids are the most prescribed drug by doctors across the globe. These drugs are highly reliable for any kind of oral problem; therefore, this segment is estimated to experience lucrative growth.
Based on formulation, the mouth ulcers treatment market is divided into sprays, mouthwash, gels, and lozenges. The gels segment held the largest share of 39% of the global revenue in 2023 due to quick healing formulas, ease of availability, and fast anti-inflammatory & anti-swelling properties. They also have anesthetic properties that provide temporary relief from the excruciating pain of sores. It is available in a variety of flavors and forms that are suitable for both adults and children.
The sprays segment is expected to post the highest CAGR during the forecast period due to low side effects, ease of availability, and quick healing of sores. They can be taken regularly to minimize harmful effects. Adults also prefer taking these formulations, as the chances of getting side effects are low in comparison to other alternatives and they provide long-term protection.
North America dominated the market with the largest revenue share of 37% in 2023. The rate of dental problems affecting people is considerably increasing in the U.S. This is attributed to an unhealthy diet, tobacco addiction, stress & trauma, and altered local immune responses. According to the United States Surgeon General's report, approximately 25% of the general population is affected by recurrent canker sores. Favorable government policies and initiatives by organizations such as the U.S. Department of Health and Human Services that are committed to boosting people's oral health across the country are anticipated to drive regional growth.
Asia Pacific is expected to grow at the fastest CAGR of 5.05% over the forecast period owing to increasing awareness about oral hygiene and supportive government initiatives. The region, on account of its wide population base and improving healthcare infrastructure, is anticipated to register the most promising growth rate during the forecast period. Besides this, vast untapped potential and increasing recognition & penetration of branded products are stimulating the growth of the regional market.
Rising awareness regarding oral treatment and practices is projected to spur the regional market growth. Moreover, increasing consumption of tobacco is expected to result in a large number of mouth ulcer cases. For instance, according to an article published by Our World in Data, nearly one in four adults in the world are daily smokers. Furthermore, the region records about 2.3 million annual deaths due to adverse effects of smoking. Increased susceptibility to mouth ulcers due to smoking is anticipated to boost the regional growth.
By Formulation
By Drug Class
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Mouth Ulcer Treatment Market
5.1. COVID-19 Landscape: Mouth Ulcer Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Mouth Ulcer Treatment Market, By Formulation
8.1. Mouth Ulcer Treatment Market, by Formulation, 2024-2033
8.1.1. Sprays
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Mouthwash
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Gels
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Lozenges
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Mouth Ulcer Treatment Market, By Drug Class
9.1. Mouth Ulcer Treatment Market, by Drug Class, 2024-2033
9.1.1. Antimicrobial
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Antihistamine
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Analgesics & Corticosteroids
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Mouth Ulcer Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Formulation (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
Chapter 11. Company Profiles
11.1. Blistex Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Church & Dwight Co, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. 3M
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Colgate Palmolive Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. GlaxoSmithKline, plc
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Bristol-Myers Squibb Company
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Pfizer, Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms